Acquisition is eighth investment by Antin’s Mid Cap Fund IPARIS & LONDON & NEW YORK--(BUSINESS WIRE)--Regulatory News:Antin Infrastructure Partners (Paris:ANTIN) has agreed with Dutch family office ...
Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalitiesInvestment enables ten new J.MD™ projects encompassing molecular optimization including, but not ...
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Fermi Inc ...
Exclusive agreement covers 13 Central and Eastern European marketsCollaboration will help expand access to VANFLYTA for ...
Locus Biosciences today announced a contract award from the National Institute of Allergy and Infectious Diseases (NIAID), ...
Approximately 60% of women will experience a UTI in their lifetime2 — Flush Advanced+ helps to reduce the risk of recurrent ...
U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S ...
Service expansions accelerate pharmacy’s achievement of 2 million shipments while maintaining industry-leading patient ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 ...
Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A ExpertiseNORFOLK, Va.--(BUSINESS WIRE)--ReAlta ...
Vygon, a leading group specialized in the design, manufacturing and marketing of medical devices in neonatology and vascular ...
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback